Key facts
- This page summarizes Cheryl R. Blanchard's Form 4 filing for Anika Therapeutics, Inc. (ANIK).
- 7 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Mar 2026, 19:42.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Award
Tax liability
Options Exercise
Tax liability
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Additional SEC filing notes
Footnote F1
Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
Footnote F2
On March 14, 2025, the Reporting Person was granted 73,559 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award.
Footnote F3
Reflects an aggregate of 14,728 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026.
Footnote F4
Reflects an aggregate of 12,104 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026.
Footnote F5
Consists of shares held by The Cheryl R. Blanchard Amended and Restated Revocable Trust dated December 19, 2014, of which the Reporting Person is a beneficiary and the sole trustee.
Footnote F6
On March 14, 2025, the Reporting Person was granted 73,559 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award.
Footnote F7
On March 15, 2024, the Reporting Person was granted 75,395 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award.